REGENTIS BIOMATERIALS LTD. (RGNT)
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Instruments & Supplies
Regentis Biomaterials Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 7.02M shares outstanding
ILRegentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life.
The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues.
The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Leadership
Ehud Geller
CEO & Executive Chairman
Arie Gordashnikov
Chief Accounting Officer
Dror Seliktar
Co-Founder & Chief Scientific Officer
Galit Reske
Chief Medical Officer
Employees
10
Country
IL
Sector
Healthcare
Website
regentis.co.il
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Valentine Keith | Director | Grant/Award | 24.8K | -- | Jul 9, 2026 |
 Alpert Susan PHD MD | Director | Grant/Award | 24.8K | -- | Jul 9, 2026 |
 Ben-Elazar Pini | Director | Grant/Award | 24.8K | -- | Jul 9, 2026 |
| Ben-Elazar Pini | Director | Grant/Award | 8.3K | -- | Jul 9, 2026 |
 Dykan Jeff | Director | Grant/Award | 12.5K | -- | Jul 9, 2026 |
| Dykan Jeff | Director | Grant/Award | 24.8K | -- | Jul 9, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Dr. Ehud Geller · may incl. warrants· filed Feb 2026 | 1.3M | 19.0% | 13G |
Rosalind Advisors, Inc. | 701.7K | 10.0% | 13F |
 Ben-Elazar Pini Director | 128.7K | 1.8% | FORM 4 |
Warberg Asset Management LLC | 87.0K | 1.2% | 13F |
JANE STREET GROUP, LLC | 43.3K | 0.6% | 13F |
RENAISSANCE TECHNOLOGIES LLC | 13.3K | 0.2% | 13F |
UBS Group AG | 434 | 0.0% | 13F |
Tower Research Capital LLC | 11 | 0.0% | 13F |
Insiders
- Valentine KeithDirector
- Alpert Susan PHD MDDirector
- Ben-Elazar PiniDirector
- Dykan JeffDirector
- GELLER EHUDChief Executive Officer
- Cohen-Arazi EfraimDirector
based on 7.02M shares outstanding
IL30d Avg
41.41K
60d Avg
48.36K
90d Avg
52.46K